Neuropsychological Indicators of SCD Progression

Cognitive Decline Clinical Trial

— SCD-CI  

Official title:

In Individuals With Subjective Cognitive Decline, Age, Memory and Action Speed Scores at Baseline Predict Progression to Cognitive Impairment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04880252
• Other study ID #: PI2019_843_0039
• Status: Completed
• Start date: May 1, 2019
• Est. completion date: May 1, 2020

Study information

• Verified date: May 2021
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Some patients with subjective cognitive decline (SCD) progress to neurocognitive disorders (NCD), whereas others remain stable; however, the neuropsychological determinants of this progression have not been identified. The investigators objective was to examine baseline neuropsychological indicators that could discriminate between people in whom the SCD progressed to a mild or major NCD and people in whom the SCD remained stable. The investigators retrospectively included patients consulting for SCD at a university medical center's memory center (Amiens, France) and who had undergone three or more neuropsychological assessments at least 6 months apart. The relationship between domain-specific scores and the global cognitive score (GCS, as a function of final status (stable SCD vs. progression toward a mild or major NCD)) was examined using a generalized linear mixed model.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: May 1, 2020
• Est. primary completion date: May 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients who had been referred to the memory center at Amiens University Medical Center (Amiens, France).
• patients who had undergone three neuropsychological assessments at least 6 months apart, from 2005
• patients who met the criteria for SCD.

Exclusion Criteria:

• patients who didn't meet the criteria for SCD

Related Conditions & MeSH terms

• Biomarkers
• Cognitive Decline
• Cognitive Dysfunction
• Disease Progression
• Neurocognitive Disorders
• Neurodegenerative Diseases
• Subjective Cognitive Decline

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variation of neuropsychological indicators (global congnitive score) between NCD et SCD patients	subjective cognitive decline (SCD) neurocognitive disorders (NCD) neuropsychological indicators could discriminate between people in whom SCD progressed to a mild or major NCD and people in whom SCD remained stable.; A global cognitive score was created using all 5 tests : Alice Heim 4-I tests inductive reasoning ; Short-term verbal memory was assessed with a 20-word free-recall test; Two measures of verbal fluency were used: phonemic and semantic; Vocabulary was assessed using the Mill Hill Vocabulary test.	one year